MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5201
+0.0366
+7.57%
After Hours: 0.5001 -0.02 -3.85% 18:17 05/20 EDT
OPEN
0.4835
PREV CLOSE
0.4835
HIGH
0.5300
LOW
0.4701
VOLUME
1.08M
TURNOVER
0
52 WEEK HIGH
1.710
52 WEEK LOW
0.2950
MARKET CAP
27.55M
P/E (TTM)
0.4108
1D
5D
1M
3M
1Y
5Y
Will Idera Pharmaceuticals (NASDAQ:IDRA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 1d ago
Why Are Idera Pharmaceuticals Shares Soaring Today
Benzinga · 3d ago
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NA...
GlobeNewswire · 3d ago
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 17, 2022: AMD, CAT, M, BILI, IDRA
Today's 5 Stock Ideas: Advanced Micro Devices (AMD) - Shares were up 3% following an upgrade by an analyst at Piper Sandler. The analyst upgraded the stock to Overweight (the equivalent of a buy rating) and set
Benzinga · 4d ago
Idera Pharma Reports Results From Investigator-Sponsored Trial In Melanoma Patients, Says 'Enrollment Stopped Early for Efficacy'
Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (NASDAQ:IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding
Benzinga · 4d ago
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
– Enrollment Stopped Early for Efficacy –EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherla...
GlobeNewswire · 4d ago
Idera Halts Enrollment in Mid-Stage Trial for Tilsotolimod in Melanoma Patients After Meeting Primary Endpoint
MT Newswires · 4d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
More
No Data
Learn about the latest financial forecast of IDRA. Analyze the recent business situations of Idera Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IDRA stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
High1.000
Average1.000
Low1.000
Current 0.5201
EPS
Actual
Estimate
-0.14-0.11-0.07-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 70
Institutional Holdings: 6.27M
% Owned: 11.83%
Shares Outstanding: 52.97M
TypeInstitutionsShares
Increased
4
46.40K
New
3
143.27K
Decreased
10
533.73K
Sold Out
6
177.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
President/Chief Executive Officer/Director
Vincent Milano
Chief Financial Officer/Senior Vice President
John Kirby
Chief Operating Officer/Senior Vice President
Daniel Soland
Senior Vice President/General Counsel/Secretary
Bryant Lim
Independent Director
Cristina Csimma
Independent Director
Michael Dougherty
Independent Director
Mark Goldberg
Independent Director
Maxine Gowen
Independent Director
Carol Schafer
No Data
No Data
About IDRA
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.